MAC
CRSP icon

Mason & Associates (California)’s CRISPR Therapeutics CRSP Stock Holding History

Mason & Associates (California)’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$384K Sell
7,048
-3
-0% -$158 0.06% 129
2026
Q1 		$313K Buy
7,051
+1,127
+19% +$59.4K 0.06% 130
2025
Q4 		$311K Buy
5,924
+24
+0.4% +$1.44K 0.06% 133
2025
Q3 		$382K Hold
5,900
– – 0.08% 92
2025
Q2 		$287K Hold
5,900
– – 0.07% 102
2025
Q1 		$201K Buy
+5,900
New +$250K 0.05% 112

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mason & Associates (California)'s CRSP Position: Q2 2026 in Review

Mason & Associates (California) reduced its CRISPR Therapeutics (CRSP) stake by 0.04% in Q2 2026, selling an estimated $158 and leaving 7,048 shares worth $384K. The position accounts for 0.06% of the portfolio, ranked #129.

Mason & Associates (California) first reported a position in CRSP in Q1 2025 and has held it in 6 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Mason & Associates (California) held 7,048 shares of CRISPR Therapeutics worth $384K as of Q2 2026.
  • Mason & Associates (California) sold 3 CRISPR Therapeutics shares in Q2 2026, an estimated $158.
  • CRISPR Therapeutics made up 0.06% of Mason & Associates (California)'s portfolio in Q2 2026, its #129 holding.
  • Mason & Associates (California) first reported a position in CRISPR Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Mason & Associates (California)'s 13F filing for Q2 2026, filed 23 Jul 2026.